novo-usd-million-29.html
Novo Annual Review 2016
30 / 71
selected portfolio company achievements in
2016
business news anokion
completed
an option deal with celgene in december
2016
. apollo endosurgery
completed
a reverse merger and was
listed
on nasdaq in december
2016
. corvus pharmaceuticals was
listed
on nasdaq in march
2016
. crispr was
listed
on nasdaq in october
2016
. irhythm was
listed
on nasdaq in october
2016
. kalvista
completed
a reverse merger and was
listed
on nasdaq in november
2016
. merus was
listed
on nasdaq in may
2016
and
completed
a major collaboration with incyte in december
2016
. ra pharmaceuticals was
listed
on nasdaq in october
2016
. reata pharmaceuticals was
listed
on nasdaq in may
2016
. tobira therapeutics was acquired by allergan in a buy-out valued up to usd 1.7 billion. product news acacia achieved positive phase 3 data in two trials in post-operative nausea and vomiting with amisulpride. allakos
completed
a phase 1 study with ak002, an antibody under development for treatment of immunologic diseases and demonstrated clinical activity with depletion of eosinophils in healthy volunteers. anaptys
completed
a phase 1 trial of anti-il33 antibody, achieving three months suppression of il-33 for three months with a single injection. colucid pharmaceuticals met the primary and secondary end points in a phase 3 pivotal study for acute migraine. ra pharmaceuticals
completed
a successful phase 1 study with an sc-administered inhibitor of c5-mediated hemolysis. spectranectis successfully
completed
a randomised study with the stellarex drug-coated balloon, meeting the end points of the study. tobira therapeutics missed the primary end point but met an important secondary end point for reduction of fibrosis in the phase 2b nash study. 30 novo a/s
2016
diseases-developing-treatment-31.html
